FDA Brief

Warning letters Drugs

FDA warning letter to

Natural Adventure, LLC

High riskIssued Apr 1, 2021Posted Apr 2, 2021Center for Drug Evaluation and Research

Natural Adventure LLC sold unapproved Purity sanitizer and essential oil products with COVID-19 treatment claims, FDA says.

What happened

FDA and FTC reviewed Natural Adventure's website and social media pages on February 26 and March 12, 2021. They found Purity Sanitizer with 70% Alcohol and Purity Essential Oil Blend offered for sale with claims that Ravintsara essential oil and the products could prevent or treat COVID-19. FDA says the products are unapproved new drugs and misbranded, and the sanitizer formulation does not fit the applicable hand sanitizer rule or FDA's temporary COVID-19 guidance.

What FDA found

  1. The products are unapproved new drugs because they are sold with claims to prevent, treat, diagnose, or cure COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded drugs, meaning their labeling or claims are false or misleading.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company introduced or delivered these products across state lines, which is prohibited for such drugs.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The hand sanitizer label claims 'anti-bacterial' essential oils that are not allowed as active ingredients under the applicable over-the-counter antiseptic rule.

    section 505G(a) of the FD&C Act; 1994 TFM as amended
  5. The hand sanitizer formulation is not consistent with FDA's temporary COVID-19 hand sanitizer guidance.

    Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)
  6. The FTC says the company lacks adequate scientific evidence for coronavirus prevention or treatment claims for Purity Essential Oil Blend.

    FTC Act, 15 U.S.C. 41 et seq.; COVID-19 Consumer Protection Act

What FDA wants

FDA and FTC ask the company to immediately stop selling the unapproved COVID-19 products and to email specific corrective steps within 48 hours, including documentation and a plan to prevent recurrence. If the company cannot complete the actions within 48 hours, it must explain the delay and give a timeline.

Who should pay attention

  • e-commerce sellers of essential oils and hand sanitizers
  • brands making health claims on websites or social media
  • quality teams reviewing COVID-19-related product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk